Starch Phosphorylase Inhibitor Is beta-Amylase
S M Pan1, T C Chang, R H Juang
1Department of Agricultural Chemistry, National Taiwan University, Taipei, Taiwan 10764, ROC.
Plant Physiology
|December 1, 1988
Summary
Sweet potato root inhibitor of starch phosphorylase is a beta-amylase. This enzyme exhibits both starch phosphorylase inhibition and beta-amylase activity, confirmed through purification and parallel testing.
Area of Science:
- Plant Biochemistry
- Enzymology
- Carbohydrate Metabolism
Background:
- Starch phosphorylase plays a key role in carbohydrate metabolism.
- Enzyme inhibitors are crucial tools for understanding metabolic pathways.
- Sweet potato (Ipomoea batatas) roots are a source of various bioactive compounds.
Purpose of the Study:
- To identify the proteinaceous noncompetitive inhibitor of starch phosphorylase isolated from sweet potato roots.
- To characterize the biochemical properties of the inhibitor.
- To elucidate the mechanism of inhibition of starch phosphorylase.
Main Methods:
- Protein purification and copurification analysis.
- Electrophoretic and immunological characterization.
- Enzyme activity assays for both starch phosphorylase inhibition and beta-amylase activity.
- Comparative analysis of biochemical properties (pH, temperature, inhibitor sensitivity).
Main Results:
- The starch phosphorylase inhibitor from sweet potato roots was identified as beta-amylase.
- The inhibitor and beta-amylase activities copurified, yielding a single protein.
- The protein was indistinguishable from commercial beta-amylase via electrophoresis and immunological methods.
- Both activities demonstrated parallel responses to varying pH, temperature, and inhibitor concentrations.
- The amylolytic pattern matched that of beta-amylase.
- Inhibition of starch phosphorylase was not due to substrate deprivation or product inhibition.
Conclusions:
- The noncompetitive inhibitor of starch phosphorylase from sweet potato roots is indeed beta-amylase.
- Beta-amylase possesses a dual function, inhibiting starch phosphorylase while also exhibiting amylolytic activity.
- The mechanism of inhibition is independent of substrate availability or the accumulation of amylolytic products.
Related Concept Videos
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Protein Kinases and Phosphatases
Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Carbohydrate Digestion
Carbohydrate digestion and metabolism break down simple and complex carbohydrates from food into saccharides (i.e., sugars) for the body to use as energy. Carbohydrate digestion starts in the mouth during mastication, or chewing. The masticated carbohydrates remain intact in the stomach. Digestion resumes in the duodenum of the small intestine, where pancreatic alpha-amylase and brush border enzymes of the microvilli convert complex carbohydrates to monosaccharides. Finally, the monosaccharides...
Biosynthesis of Polysaccharides
Polysaccharides such as glycogen and starch are synthesized from nucleoside diphosphate sugars, primarily uridine diphosphate glucose (UDPG) and adenosine diphosphate glucose (ADPG). These activated glucose donors act as key intermediates in carbohydrate metabolism and biosynthesis. UDPG primarily involves glycogen synthesis in animals and many bacteria, while ADPG plays a fundamental role in starch synthesis in plants and certain bacteria.UDPG is formed when glucose-1-phosphate reacts with...

